Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML0937

Sigma-Aldrich

Darunavir

≥98% (HPLC)

Sinónimos:

TMC-114, UIC-94017, [(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4- [(4-aminophenyl)sulfonyl- (2-methylpropyl)amino]-3-hydroxy-1-phenyl- butan-2-yl]

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

10 MG
US$ 121,75
50 MG
US$ 509,03

US$ 121,75

En stockDesdeSAINT LOUIS

Para encargar productos, Contacto su distribuidor local.
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
10 MG
US$ 121,75
50 MG
US$ 509,03

About This Item

Fórmula empírica (notación de Hill):
C27H37N3O7S
Número de CAS:
206361-99-1
Peso molecular:
547.66
Número MDL:
MFCD09260006
Código UNSPSC:
51111800
ID de la sustancia en PubChem:
329825618
NACRES:
NA.77

US$ 121,75

En stockDesdeSAINT LOUIS

Para encargar productos, Contacto su distribuidor local.

Nivel de calidad

100

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated

color

white to beige

solubilidad

DMSO: 20 mg/mL, clear

Condiciones de envío

wet ice

temp. de almacenamiento

−20°C

cadena SMILES

[H][C@]1([C@@H](OC(N[C@@H](CC2=CC=CC=C2)[C@@H](CN(S(C3=CC=C(N)C=C3)(=O)=O)CC(C)C)O)=O)CO4)[C@]4([H])OCC1

InChI

1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

Clave InChI

CJBJHOAVZSMMDJ-HEXNFIEUSA-N

Acciones bioquímicas o fisiológicas

Darunavir has been sanctioned by the food and drug administration (FDA) as the first treatment of drug-resistant human immunodeficiency virus (HIV).[1]
Darunavir is a HIV protease inhibitor; antiretroviral.
Darunavir is a second-generation antiviral HIV protease inhibitor with broad spectrum activity.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000313550
0000313550
0000164814
126M4763V
054M4703V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Michael S Saag et al.
JAMA, 320(4), 379-396 (2018-07-26)
Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. To evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for
Beatriz Grinsztejn et al.
The lancet. HIV, 6(9), e588-e600 (2019-08-03)
Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring. We aimed to evaluate use of newer antiretroviral drugs and contemporary
Ninon Taylor et al.
Journal of acquired immune deficiency syndromes (1999), 75(1), e13-e20 (2016-11-01)
Hemeoxygenase-1 (HO-1) has recently been identified as a major driver of metaflammation and obesity-related insulin resistance (IR). Drug-induced IR increases cardiovascular risk within the HIV-1-infected population receiving antiretroviral therapy (ART). We therefore investigated a possible role of HO-1 in ART-induced
Joseph J Eron et al.
AIDS (London, England), 32(11), 1431-1442 (2018-04-24)
To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infected adults. Phase-3, randomized, active-controlled, double-blind, international, multicenter, noninferiority study (NCT02431247). Seven hundred and twenty-five participants
Thomas N Kakuda et al.
Antiviral therapy, 19(6), 597-606 (2014-06-26)
Darunavir requires pharmacokinetic enhancement to increase its bioavailability. Cobicistat is potentially an alternative pharmacokinetic booster to ritonavir. Bioequivalence of a darunavir/cobicistat fixed-dose combination (FDC) versus darunavir and cobicistat co-administered as single agents and the effect of a high-fat meal on
Ver todos los artículos relacionados

Artículos

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico